Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy

Blessy George, Melanie S Joy, Lauren M Aleksunes, Blessy George, Melanie S Joy, Lauren M Aleksunes

Abstract

Despite recent progress in the development of novel approaches to treat cancer, traditional antineoplastic drugs, such as cisplatin, remain a mainstay of regimens targeting solid tumors. Use of cisplatin is limited by acute kidney injury, which occurs in approximately 30% of patients. Current clinical measures, such as serum creatinine and estimated glomerular filtration rate, are inadequate in their ability to detect acute kidney injury, particularly when there is only a moderate degree of injury. Thus, there is an urgent need for improved diagnostic biomarkers to predict nephrotoxicity. There is also interest by the U.S. Food and Drug Administration to validate and implement new biomarkers to identify clinical and subclinical acute kidney injury in patients during the drug approval process. This minireview provides an overview of the current literature regarding the utility of urinary proteins (albumin, beta-2-microglobulin, N-acetyl-D-glucosaminidase, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and cystatin C) as biomarkers for cisplatin-induced AKI. Many of the well-studied urinary proteins (KIM-1, NGAL, B2M, albumin) as well as emerging biomarkers (calbindin, monocyte chemotactic protein-1, and trefoil factor 3) display distinct patterns of time-dependent excretion after cisplatin administration. Implementation of these biomarker proteins in the oncology clinic has been hampered by a lack of validation studies. To address these issues, large head-to-head studies are needed to fully characterize time-dependent responses and establish accurate cutoff values and ranges, particularly in cancer patients. Impact statement There is growing interest in using urinary protein biomarkers to detect acute kidney injury in oncology patients prescribed the nephrotoxic anticancer drug cisplatin. We aim to synthesize and organize the existing literature on biomarkers examined clinically in patients receiving cisplatin-containing chemotherapy regimens. This minireview highlights several proteins (kidney injury molecule-1, beta-2-microglobulin, neutrophil gelatinase-associated lipocalin, calbindin, monocyte chemotactic protein-1, trefoil factor 3) with the greatest promise for detecting cisplatin-induced acute kidney injury in humans. A comprehensive review of the existing literature may aid in the design of larger studies needed to implement the clinical use of these urinary proteins as biomarkers of kidney injury.

Keywords: Urinary biomarkers; acute kidney injury; cisplatin; kidney injury molecule-1; neutrophil gelatinase-associated lipocalin.

References

    1. Shord SS, Thompson DM, Krempl GA, Hanigan MH. Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer. Anticancer Drugs 2006; 17:207–15
    1. Kociba RJ, Sleight SD. Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat. Cancer Chemother Rep 1971; 55:1–8
    1. Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 1977; 39:1362–71
    1. Dentino M, Luft FC, Yum MN, Williams SD, Einhorn LH. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 1978; 41:1274–81
    1. Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 2009; 296:F505–11
    1. Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J, Schlatter E. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005; 167:1477–84
    1. Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of cisplatin with the human organic cation transporter 2. Clin Cancer Res 2008; 14:3875–80
    1. Pascoe JM, Roberts JJ. Interactions between mammalian cell DNA and inorganic platinum compounds. I. DNA interstrand cross-linking and cytotoxic properties of platinum(II) compounds. Biochem Pharmacol 1974; 23:1359–65
    1. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003; 14:1–10
    1. Townsend DM, Hanigan MH. Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther 2002; 300:142–8
    1. Zhang L, Hanigan MH. Role of cysteine S-conjugate beta-lyase in the metabolism of cisplatin. J Pharmacol Exp Ther 2003; 306:988–94
    1. Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett 2015; 237:219–27
    1. Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD. Long-Term Renal Outcomes after Cisplatin Treatment. Clin J Am Soc Nephrol 2016; 11:1173–9
    1. Chen Y. Assessing and predicting drug-induced kidney injury, functional change, and safety in preclinical studies in rats. In: Will Y, McDuffie JE, Olaharski AJ, Jeffy BD (eds) Drug discovery toxicology: from target assessment to translational biomarkers Hoboken, New Jersey: John Wiley & Sons, Inc., 2016, pp.431–42
    1. Dieterle F, Sistare F, Goodsaid F, Papaluca M, Ozer JS, Webb CP, Baer W, Senagore A, Schipper MJ, Vonderscher J, Sultana S, Gerhold DL, Phillips JA, Maurer G, Carl K, Laurie D, Harpur E, Sonee M, Ennulat D, Holder D, Andrews-Cleavenger D, Gu YZ, Thompson KL, Goering PL, Vidal JM, Abadie E, Maciulaitis R, Jacobson-Kram D, Defelice AF, Hausner EA, Blank M, Thompson A, Harlow P, Throckmorton D, Xiao S, Xu N, Taylor W, Vamvakas S, Flamion B, Lima BS, Kasper P, Pasanen M, Prasad K, Troth S, Bounous D, Robinson-Gravatt D, Betton G, Davis MA, Akunda J, McDuffie JE, Suter L, Obert L, Guffroy M, Pinches M, Jayadev S, Blomme EA, Beushausen SA, Barlow VG, Collins N, Waring J, Honor D, Snook S, Lee J, Rossi P, Walker E, Mattes W. Renal biomarker qualification submission: a dialog between the FDA-EMEA and predictive safety testing consortium. Nat Biotechnol 2010; 28:455–62
    1. Ronco C, Kellum JA, Haase M. Subclinical AKI is still AKI. Crit Care 2012; 16:313.
    1. USFDA. Letter of support for drug-induced (DIKI) renal tubular injury biomarkers, (accessed 17 November 2017).
    1. Waikar SS, Betensky RA, Emerson SC, Bonventre JV. Imperfect gold standards for kidney injury biomarker evaluation. J Am Soc Nephrol 2012; 23:13–21
    1. Waikar SS, Betensky RA, Emerson SC, Bonventre JV. Imperfect gold standards for biomarker evaluation. Clin Trials 2013; 10:696–700
    1. Peterson PA, Evrin PE, Berggard I. Differentiation of glomerular, tubular, and normal proteinuria: determinations of urinary excretion of beta-2-macroglobulin, albumin, and total protein. J Clin Invest 1969; 48:1189–98
    1. Lin HY, Lee SC, Lin SF, Hsiao HH, Liu YC, Yang WC, Hwang DY, Hung CC, Chen HC, Guh JY. Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatin-induced acute kidney injury better than albuminuria or urinary cystatin C levels. Kaohsiung J Med Sci 2013; 29:304–11
    1. Pfaller W, Thorwartl U, Nevinny-Stickel M, Krall M, Schober M, Joannidis M, Hobisch A. Clinical value of fructose 1,6 bisphosphatase in monitoring renal proximal tubular injury. Kidney Int Suppl 1994; 47:S68–75
    1. Takeda M, Komeyama T, Tsutsui T, Mizusawa T, Go H, Hatano A, Tanikawa T. Urinary endothelin-1-like immunoreactivity in young male patients with testicular cancer treated by cis-platinum: comparison with other urinary parameters. Clin Sci 1994; 86:703–7
    1. Takeda M, Komeyama T, Tsutsui T, Mizusawa T, Go H, Hatano A, Tanikawa T. Changes in urinary excretion of endothelin-1-like immunoreactivity in patients with testicular cancer receiving high-dose cisplatin therapy. Am J Kidney Dis 1994; 24:12–6
    1. Fleming JJ, Collis C, Peckham MJ. Renal damage after cis-platinum. Lancet 1979; 2:960
    1. Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssac PP. Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 1988; 44:164–72
    1. Daugaard G, Rossing N, Rorth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 1988; 21:163–7
    1. Johnsson A, Hoglund P, Grubb A, Cavallin SE. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus. Cancer Chemother Pharmacol 1996; 39:25–33
    1. Fuke Y, Fujita T, Satomura A, Endo M, Matsumoto K. The role of complement activation, detected by urinary C5b-9 and urinary factor H, in the excretion of urinary albumin in cisplatin nephropathy. Clin Nephrol 2009; 71:110–7
    1. Verplanke AJ, Herber RF, de Wit R, Veenhof CH. Comparison of renal function parameters in the assessment of cis-platin induced nephrotoxicity. Nephron 1994; 66:267–72
    1. George B, Wen X, Mercke N, Gomez M, O'bryant C, Bowles DW, Hu Y, Hogan SL, Joy MS, Aleksunes LM. Profiling of kidney injury biomarkers in patients receiving cisplatin: time-dependent changes in the absence of clinical nephrotoxicity. Clin Pharmacol Ther 2017; 101:510–8
    1. Tirelli AS, Colombo N, Cavanna G, Mangioni C, Assael BM. Follow-up study of enzymuria and beta 2 microglobulinuria during cis-platinum treatment. Eur J Clin Pharmacol 1985; 29:313–8
    1. Sorensen PG, Nissen MH, Groth S, Rorth M. Beta-2-microglobulin excretion: an indicator of long term nephrotoxicity during cis-platinum treatment? Cancer Chemother Pharmacol 1985; 14:247–9
    1. Buamah PK, Howell A, Whitby H, Harpur ES, Gescher A. Assessment of renal function during high-dose CIS-platinum therapy in patients with ovarian carcinoma. Cancer Chemother Pharmacol 1982; 8:281–4
    1. Cohen AI, Harberg J, Citrin DL. Measurement of urinary beta 2-microglobulin in the detection of cisplatin nephrotoxicity. Cancer Treat Rep 1981; 65:1083–5
    1. Takashi M, Zhu Y, Miyake K, Kato K. Urinary 28-kD calbindin-D as a new marker for damage to distal renal tubules caused by cisplatin-based chemotherapy. Urol Int 1996; 56:174–9
    1. Shinke H, Masuda S, Togashi Y, Ikemi Y, Ozawa A, Sato T, Kim YH, Mishima M, Ichimura T, Bonventre JV, Matsubara K. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. Cancer Chemother Pharmacol 2015; 76:989–96
    1. de Gislain C, Dumas M, D'athis P, Lautissier JL, Escousse A, Guerrin J. Urinary beta 2-microglobulin: early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide. Cancer Chemother Pharmacol 1986; 18:276–9
    1. Jones BR, Bhalla RB, Mladek J, Kaleya RN, Gralla RJ, Alcock NW, Schwartz MK, Young CW, Reidenberg MM. Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clin Pharmacol Ther 1980; 27:557–62
    1. Ikeda H, Nagashima K, Okumura H, Takahashi A, Matsuyama S, Nagamachi Y. Urinary excretion of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in advanced neuroblastoma patients receiving cis-diamminedichloroplatinum(II). Eur J Surg Oncol 1988; 14:17–20
    1. Brillet G, Deray G, Jacquiaud C, Mignot L, Bunker D, Meillet D, Raymond F, Jacobs C. Long-term renal effect of cisplatin in man. Am J Nephrol 1994; 14:81–4
    1. Le Hir M, Dubach UC, Schmidt U. Quantitative distribution of lysosomal hydrolases in the rat nephron. Histochemistry 1979; 63:245–51
    1. Hong CY, Chia KS. Markers of diabetic nephropathy. J Diab Compl 1998; 12:43–60
    1. Goren MP, Forastiere AA, Wright RK, Horowitz ME, Dodge RK, Kamen BA, Viar MJ, Pratt CB. Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. Cancer Chemother Pharmacol 1987; 19:57–60
    1. Hosohata K, Washino S, Kubo T, Natsui S, Fujisaki A, Kurokawa S, Ando H, Fujimura A, Morita T. Early prediction of cisplatin-induced nephrotoxicity by urinary vanin-1 in patients with urothelial carcinoma. Toxicology 2016; 359–360:71–5
    1. Diener U, Knoll E, Langer B, Rautenstrauch H, Ratge D, Wisser H. Urinary excretion of N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase in patients receiving amikacin or cis-platinum. Clin Chim Acta 1981; 112:149–57
    1. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, Sanicola M. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998; 273:4135–42
    1. Ichimura T, Asseldonk EJ, Humphreys BD, Gunaratnam L, Duffield JS, Bonventre JV. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest 2008; 118:1657–68
    1. Tekce BK, Uyeturk U, Tekce H, Uyeturk U, Aktas G, Akkaya A. Does the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage? Ann Clin Biochem 2015; 52:88–94
    1. Pianta TJ, Pickering JW, Succar L, Chin M, Davidson T, Buckley NA, Mohamed F, Endre ZH. Dexamethasone modifies cystatin C-based diagnosis of acute kidney injury during cisplatin-based chemotherapy. Kidney Blood Press Res 2017; 42:62–75
    1. Pavkovic M, Robinson-Cohen C, Chua AS, Nicoara O, Cardenas-Gonzalez M, Bijol V, Ramachandran K, Hampson L, Pirmohamed M, Antoine DJ, Frendl G, Himmelfarb J, Waikar SS, Vaidya VS. Detection of drug-induced acute kidney injury in humans using urinary KIM-1, miR-21, -200c, and -423. Toxicol Sci 2016; 152:205–13
    1. Xu S, Venge P. Lipocalins as biochemical markers of disease. Biochim Biophys Acta 2000; 1482:298–307
    1. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, Du T, Erdjument-Bromage H, Tempst P, Strong R, Barasch J. An iron delivery pathway mediated by a lipocalin. Mol Cell 2002; 10:1045–56
    1. Kjeldsen L, Cowland JB, Borregaard N. Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta 2000; 1482:272–83
    1. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003; 14:2534–43
    1. Shahbazi F, Sadighi S, Dashti-Khavidaki S, Shahi F, Mirzania M. Urine ratio of neutrophil gelatinase-associated lipocalin to creatinine as a marker for early detection of cisplatin-associated nephrotoxicity. Iran J Kidney Dis 2015; 9:306–10
    1. Gaspari F, Cravedi P, Mandala M, Perico N, de Leon FR, Stucchi N, Ferrari S, Labianca R, Remuzzi G, Ruggenenti P. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. Nephron Clin Pract 2010; 115:c154–60
    1. Sterling M, Al-Ismaili Z, McMahon KR, Piccioni M, Pizzi M, Mottes T, Lands LC, Abish S, Fleming AJ, Bennett MR, Palijan A, Devarajan P, Goldstein SL, O'brien MM, Zappitelli M. Urine biomarkers of acute kidney injury in noncritically ill, hospitalized children treated with chemotherapy. Pediatr Blood Cancer 2017; 64:e26538
    1. Karademir LD, Dogruel F, Kocyigit I, Yazici C, Unal A, Sipahioglu MH, Oymak O, Tokgoz B. The efficacy of theophylline in preventing cisplatin-related nephrotoxicity in patients with cancer. Ren Fail 2016; 38:806–14
    1. Seker MM, Deveci K, Seker A, Sancakdar E, Yilmaz A, Turesin AK, Kacan T, Babacan NA. Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury. Asian Pac J Cancer Prev 2015; 16:407–10
    1. Kos FT, Sendur MA, Aksoy S, Celik HT, Sezer S, Civelek B, Yaman S, Zengin N. Evaluation of renal function using the level of neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy. Asian Pac J Cancer Prev 2013; 14:1111–4
    1. Benohr P, Grenz A, Hartmann JT, Muller GA, Blaschke S. Cystatin C – a marker for assessment of the glomerular filtration rate in patients with cisplatin chemotherapy. Kidney Blood Press Res 2006; 29:32–5
    1. Kos FT, Sendur MA, Aksoy S, Sezer S, Civelek B, Yazici O, Yaman S, Eren T, Zengin N. Evaluation of the renal function using cystatin C level in the patients receiving cisplatin-based chemotherapy. Ren Fail 2013; 35:705–10
    1. Risch L, Huber AR. Glucocorticoids and increased serum cystatin C concentrations. Clin Chim Acta 2002; 320:133–4
    1. Bokenkamp A, van Wijk JA, Lentze MJ, Stoffel-Wagner B. Effect of corticosteroid therapy on serum cystatin C and beta2-microglobulin concentrations. Clin Chem 2002; 48:1123–6
    1. Manetti L, Pardini E, Genovesi M, Campomori A, Grasso L, Morselli LL, Lupi I, Pellegrini G, Bartalena L, Bogazzi F, Martino E. Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest 2005; 28:346–9
    1. Zhang J, Zhou W. Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem Toxicol 2012; 50:2289–93
    1. Bredderman PJ, Wasserman RH. Chemical composition, affinity for calcium, and some related properties of the vitamin D dependent calcium-binding protein. Biochemistry 1974; 13:1687–94
    1. Won AJ, Kim S, Kim YG, Kim KB, Choi WS, Kacew S, Kim KS, Jung JH, Lee BM, Kim S, Kim HS. Discovery of urinary metabolomic biomarkers for early detection of acute kidney injury. Mol Biosyst 2016; 12:133–44
    1. Togashi Y, Sakaguchi Y, Miyamoto M, Miyamoto Y. Urinary cystatin C as a biomarker for acute kidney injury and its immunohistochemical localization in kidney in the CDDP-treated rats. Exp Toxicol Pathol 2012; 64:797–805
    1. Toprak Z, Cebeci E, Helvaci SA, Toprak ID, Kutlu Y, Sakin A, Tukek T. Cisplatin nephrotoxicity is not detected by urinary cell-cycle arrest biomarkers in lung cancer patients. Int Urol Nephrol 2017; 49:1041–7
    1. Chang C, Hu Y, Hogan S, Mercke N, Gomez M, O'bryant C, Bowles D, George B, Wen X, Gist K, Aleksunes L, Joy M. The product of tissue inhibitor of metalloproteinase (TIMP2) and insulin like growth factor binding protein 7 (IGFBP7) is elevated at baseline in ambulatory cancer patients prescribed cisplatin. JSM Biomark 2017; 3:1009
    1. Schanz M, Hoferer A, Shi J, Alscher MD, Kimmel M. Urinary TIMP2IGFBP7 for the prediction of platinum-induced acute renal injury. Int J Nephrol Renovasc Dis 2017; 10:175–81
    1. Aregger F, Uehlinger DE, Witowski J, Brunisholz RA, Hunziker P, Frey FJ, Jorres A. Identification of IGFBP-7 by urinary proteomics as a novel prognostic marker in early acute kidney injury. Kidney Int 2014; 85:909–19
    1. Bigg HF, Morrison CJ, Butler GS, Bogoyevitch MA, Wang Z, Soloway PD, Overall CM. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Cancer Res 2001; 61:3610–8
    1. Emlet DR, Pastor-Soler N, Marciszyn A, Wen X, Gomez H, Humphries WHt, Morrisroe S, Volpe JK, Kellum JA. Insulin-like growth factor binding protein 7 and tissue inhibitor of metalloproteinases-2: differential expression and secretion in human kidney tubule cells. Am J Physiol Renal Physiol 2017; 312:F284–F96
    1. Correa-Rotter R, Ibarra-Rubio ME, Schwochau G, Cruz C, Silkensen JR, Pedraza-Chaverri J, Chmielewski D, Rosenberg ME. Induction of clusterin in tubules of nephrotic rats. J Am Soc Nephrol 1998; 9:33–7
    1. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995; 27:633–45
    1. Prodjosudjadi W, Daha MR, Gerritsma JS, Florijn KW, Barendregt JN, Bruijn JA, van der Woude FJ, van Es LA. Increased urinary excretion of monocyte chemoattractant protein-1 during acute renal allograft rejection. Nephrol Dial Transplant 1996; 11:1096–103
    1. Nishihara K, Masuda S, Shinke H, Ozawa A, Ichimura T, Yonezawa A, Nakagawa S, Inui K, Bonventre JV, Matsubara K. Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicity. Biochem Pharmacol 2013; 85:570–82
    1. Du TY, Luo HM, Qin HC, Wang F, Wang Q, Xiang Y, Zhang Y. Circulating serum trefoil factor 3 (TFF3) is dramatically increased in chronic kidney disease. PLoS One 2013; 8:e80271.
    1. Yu Y, Jin H, Holder D, Ozer JS, Villarreal S, Shughrue P, Shi S, Figueroa DJ, Clouse H, Su M, Muniappa N, Troth SP, Bailey W, Seng J, Aslamkhan AG, Thudium D, Sistare FD, Gerhold DL. Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat Biotechnol 2010; 28:470–7
    1. Kinoshita K, Taupin DR, Itoh H, Podolsky DK. Distinct pathways of cell migration and antiapoptotic response to epithelial injury: structure-function analysis of human intestinal trefoil factor. Mol Cell Biol 2000; 20:4680–90
    1. Wadey RM, Pinches MG, Jones HB, Riccardi D, Price SA. Tissue expression and correlation of a panel of urinary biomarkers following cisplatin-induced kidney injury. Toxicol Pathol 2014; 42:591–602
    1. Harrison DJ, Kharbanda R, Cunningham DS, McLellan LI, Hayes JD. Distribution of glutathione S-transferase isoenzymes in human kidney: basis for possible markers of renal injury. J Clin Pathol 1989; 42:624–8
    1. McMahon BA, Koyner JL, Murray PT. Urinary glutathione S-transferases in the pathogenesis and diagnostic evaluation of acute kidney injury following cardiac surgery: a critical review. Curr Opin Crit Care 2010; 16:550–5
    1. Gautier JC, Riefke B, Walter J, Kurth P, Mylecraine L, Guilpin V, Barlow N, Gury T, Hoffman D, Ennulat D, Schuster K, Harpur E, Pettit S. Evaluation of novel biomarkers of nephrotoxicity in two strains of rat treated with Cisplatin. Toxicol Pathol 2010; 38:943–56
    1. Harpur E, Ennulat D, Hoffman D, Betton G, Gautier JC, Riefke B, Bounous D, Schuster K, Beushausen S, Guffroy M, Shaw M, Lock E, Pettit S, Nephrotoxicity HCoBo. Biological qualification of biomarkers of chemical-induced renal toxicity in two strains of male rat. Toxicol Sci 2011; 122:235–52
    1. McDuffie JE, Ma JY, Sablad M, Sonee M, Varacallo L, Louden C, Guy A, Vegas J, Liu X, La D, Snook S. Time course of renal proximal tubule injury, reversal, and related biomarker changes in rats following cisplatin administration. Int J Toxicol 2013; 32:251–60
    1. Yan J, Gong Y, She YM, Wang G, Roberts MS, Burczynski FJ. Molecular mechanism of recombinant liver fatty acid binding protein's antioxidant activity. J Lipid Res 2009; 50:2445–54
    1. Maatman RG, Van Kuppevelt TH, Veerkamp JH. Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization. Biochem J 1991; 273:759–66
    1. Negishi K, Noiri E, Sugaya T, Li S, Megyesi J, Nagothu K, Portilla D. A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure. Kidney Int 2007; 72:348–58
    1. Fuchs TC, Frick K, Emde B, Czasch S, von Landenberg F, Hewitt P. Evaluation of novel acute urinary rat kidney toxicity biomarker for subacute toxicity studies in preclinical trials. Toxicol Pathol 2012; 40:1031–48
    1. Pianta TJ, Succar L, Davidson T, Buckley NA, Endre ZH. Monitoring treatment of acute kidney injury with damage biomarkers. Toxicol Lett 2017; 268:63–70
    1. Pinches MD, Betts CJ, Bickerton SJ, Beattie L, Burdett LD, Thomas HT, Derbyshire NA, Moores M, Price SA. Evaluation of novel urinary renal biomarkers: biological variation and reference change values. Toxicol Pathol 2012; 40:541–9
    1. Vinken P, Starckx S, Barale-Thomas E, Looszova A, Sonee M, Goeminne N, Versmissen L, Buyens K, Lampo A. Tissue Kim-1 and urinary clusterin as early indicators of cisplatin-induced acute kidney injury in rats. Toxicol Pathol 2012; 40:1049–62

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться